Article Text

Short report
Adult-onset spinocerebellar ataxia syndromes due to MTATP6 mutations
  1. Gerald Pfeffer1,2,
  2. Emma L Blakely3,
  3. Charlotte L Alston3,
  4. Adam Hassani1,
  5. Mike Boggild4,
  6. Rita Horvath1,
  7. David C Samuels5,
  8. Robert W Taylor3,
  9. Patrick F Chinnery1
  1. 1Institute of Genetic Medicine, Newcastle University, Newcastle, UK
  2. 2Clinician Investigator Program, University of British Columbia, Vancouver, Canada
  3. 3Mitochondrial Research Group, Newcastle University, Newcastle, UK
  4. 4The Walton Centre, Liverpool, UK
  5. 5Center for Human Genetics Research, Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
  1. Correspondence to Professor Patrick F Chinnery, Institute of Genetic Medicine, Central Parkway, Newcastle, NE1 3BZ, UK; patrick.chinnery{at}


Background Spinocerebellar ataxia syndromes presenting in adulthood have a broad range of causes, and despite extensive investigation remain undiagnosed in up to ∼50% cases. Mutations in the mitochondrially encoded MTATP6 gene typically cause infantile-onset Leigh syndrome and, occasionally, have onset later in childhood. The authors report two families with onset of ataxia in adulthood (with pyramidal dysfunction and/or peripheral neuropathy variably present), who are clinically indistinguishable from other spinocerebellar ataxia patients.

Methods Genetic screening study of the MTATP6 gene in 64 pedigrees with unexplained ataxia, and case series of two families who had MTATP6 mutations.

Results Three pedigrees had mutations in MTATP6, two of which have not been reported previously and are detailed in this report. These families had the m.9185T>C and m.9035T>C mutations, respectively, which have not previously been associated with adult-onset cerebellar syndromes. Other investigations including muscle biopsy and respiratory chain enzyme activity were non-specific or normal.

Conclusions MTATP6 sequencing should be considered in the workup of undiagnosed ataxia, even if other investigations do not suggest a mitochondrial DNA disorder.

  • MTATP6
  • ATPase
  • mitochondria
  • ataxia
  • spinocerebellar ataxia
  • neuropathy
  • adult-onset
  • clinical neurology
  • mitochondrial disorders
  • muscular dystrophy
  • muscle disease
  • neurogenetics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Mutations in the mitochondrial-encoded MTATP6 gene typically cause severe neonatal or childhood-onset multisystem neurological diseases including Leigh syndrome and neuropathy, ataxia and pigmentary retinopathy. Although late-onset forms have been described, the phenotype is usually an axonal sensorimotor neuropathy, occasionally accompanied by associated ataxia.1–3 Screening for MTATP6 mutations is not routinely considered in the investigative work-up in cases of adult-onset spinocerebellar ataxia. In this study, we describe two families with adult-onset spinocerebellar ataxia due to mutations in MTATP6, indicating the importance of sequencing this gene in this specific context.


Institutional research ethics board approval was obtained, and patients provided written informed consent. We studied 64 pedigrees with ataxia after excluding common sporadic and inherited causes (inflammatory, metabolic, neoplastic and sporadic degenerative ataxia, spinocerebellar ataxia 1, 2, 3, 6, 7, 10, 12 or 17, dentatorubral-pallidoluysian atrophy or Friedreich ataxia). Sequencing of the MTATP6 gene was performed on all pedigrees. In pedigrees with identified MTATP6 mutations, the clinical records and investigations of all available family members were reviewed in detail, and the heteroplasmy level of the mutation was quantified using pyrosequencing assays.

Sequencing of MTATP6 gene

Total genomic DNA was extracted from several tissues including muscle and blood using standard procedures. Direct sequencing of the MTATP6 gene was undertaken employing three overlapping pairs of M13-tagged oligodeoxynucleotide primers as follows: MTATP6a-Fw 5′-CGGGGGTATACTACGGTCAA-3′ (m.8151-8170) and MTATP6a-Rv 5′-TCCGAGGAGGTTAGTTGTGG-3′ (m.8765-8784); MTATP6b-Fw 5′-ACCACCCAACAATGACTAATC-3′ (m.8656-8676) and MTATP6b-Rv 5′-GTTGTCGTGCAGGTAGAGG-3′ (m.9183-9201); MTATP6c-Fw 5′-ATCCTAGAAATCGCTGTCGC-3′ (m.9127-9146) and MTATP6c-Rv 5′-ATTAGACTATGGTGAGCTCAG-3′ (m.9641-9661). Amplified PCR products were sequenced using BigDye Terminator V.3.1 chemistries (Applied Biosystems, Warrington, UK) and compared with the revised Cambridge reference sequence (GenBank Accession number NC_012920.1).4

Measurement of heteroplasmy with pyrosequencing assays

The mitochondrial DNA (mtDNA) mutation load levels were quantified using sensitive pyrosequencing assays according to the manufacturer's standard protocol. Pyromark Assay Design Software V.2.0 (Qiagen, West Sussex, UK) was used to design locus-specific PCR and pyrosequencing primers for the m.9035T>C and m.9185T>C mutations. PCR of mtDNA amplicons spanning the m.9035 nucleotide was achieved using the following primers: 9035_Fw: 5′-CCGTACGCCTAACCGCTAACAT-3′ (m.8996-9018) and 9035_Rv 5′-AGGGTGGCGCTTCCAATT-3′ (m.9045-9062).

Pyrosequencing was carried out on the Pyromark Q24 platform according to the manufacturer's protocol, using mutation-specific pyrosequencing primers 9035_Pyro: 5′-ACTGCAGGCCACCTAC-3′ (m.9019-9034). The primers used to quantify the m.9185T>C mutation are as follows: 9185_Fw: CGCCTTAATCCAAGCCTACGTT (m.9144-9165) and 9185_Rv: GTGATTGGTGGGTCATTATGTGTT (m.9199-9222) and 9185_Pyro: CGTTTTCACACTTCTAGTAA (m.9162-9181). The reverse PCR primers for both assays were biotinylated. Pyromark Q24 software was used to quantify the m.9035T>C and m.9185T>C heteroplasmy levels through comparison of wild-type and mutant peak heights.5


Three families were identified, each with different MTATP6 mutations (m.8993T>C, m.9035T>C and m.9185T>C). One family was reported previously.2 The two families who had not been previously reported are presented below, and pedigree structure is illustrated in figure 1.

Figure 1

Complete pedigrees for families A and B. All members of generation I are affected by adult-onset ataxic disorders. The family members of generation II are unaffected (except for B:II-1), although because of their young age, some or all, may yet develop the condition in adulthood.

  • Family A. All five siblings in the same generation presented with a spinocerebellar syndrome in late teenage years or early adult life (table 1). Each tested sibling harboured very high levels of the m.9185T>C mutation in blood or muscle. Their parents lived into their 70's and were not known to have a neurological disorder.

  • Family B. All three siblings in the same generation had a spinocerebellar syndrome (table 1). Each tested sibling harboured very high levels of the m.9035T>C mutation in blood. The parents were not known to have any neurological illness. Patient I-3 has two children aged 11 and 8 years who are presently healthy; and they had a stillbirth at 37 weeks. Patient I-1 has one child aged 4 years, identified as II-1 in the table 1, who developed symptoms at 2 years of age.

Table 1

Clinical features and testing results


The m.9185T>C mutation (predicted to cause amino acid substitution p.L170P) has been described previously in three families. Ataxia was a prominent feature in several family members from two of these reports, but onset was in childhood.6 ,7 One report demonstrated broad phenotypic variability between family members carrying this mutation at similar levels of heteroplasmy.6 Our patients from family A who had this mutation, all had onset of disease in adulthood, with ataxia as the predominant feature, despite high levels of heteroplasmy (95%–99%) in all family members tested.

The m.9035T>C mutation (causing amino acid substitution p.L220P, which was present in family B) has been reported in one family with childhood ataxia and developmental delay.8 With the exception of one patient (designated II-1 in table 1), our patients with this mutation have a much milder phenotype, with adult-onset of a spinocerebellar syndrome and no developmental delay, expanding the phenotypic spectrum for this mutation, and again indicating that onset of disease may occur in adulthood despite high heteroplasmy levels (90–96%).

With the cases described here, three separate MTATP6 mutations have now been shown to cause adult-onset spinocerebellar ataxia syndromes (m.8993T>C,1 ,2 and m.9035T>C or m.9185T>C), with a broad range of phenotypes. In our families, this most characteristically included cerebellar dysfunction (midline, appendicular, ocular and dysarthria), pyramidal dysfunction (spasticity and/or abnormal reflexes), neuropathy (sensorimotor or motor axonal neuropathy), or proximal myopathy. Routine clinical diagnostic tests were non-specific: brain MRI was normal in 3/5 patients and one patient each had cerebellar atrophy, or cerebellar and cerebral volume loss. Nerve conduction studies and electromyography indicated the presence of mild sensorimotor axonal neuropathy in 3/6 patients, and one patient each with motor axonal neuropathy, myopathic changes and radiculopathy. Muscle biopsy was performed in three patients and demonstrated normal results, non-specific abnormalities and minor myopathic changes, respectively. Respiratory chain enzyme analysis was performed on muscle from two patients in family A, with normal activity in complexes I–IV. Although the number of patients is small, the data indicate that diagnostic investigations appear to be non-specific in these two families with ataxia due to MTATP6 mutations. Of particular importance is that none of the three patients with muscle biopsy had the typical findings of mitochondrial disease, with normal respiratory chain enzyme activities in frozen muscle homogenates. These features are typical for adult onset spinocerebellar ataxia, and when presented with these investigations the level of suspicion may be low for an mtDNA disorder.

Genetic testing results, and measurement of heteroplasmy levels using pyrosequencing, have demonstrated high mtDNA heteroplasmy levels in all patients, including those from other reports 1–3 In our families, six patients had their genetic testing performed on leucocyte DNA, with heteroplasmy levels ranging from 90% to 99%. Two patients who had testing on DNA extracted from muscle had similar heteroplasmy levels (96–98%). Therefore, unlike many mtDNA disorders, MTATP6 sequencing can be reliably performed on leucocyte DNA, and should be considered as a diagnostic test in the work up of ataxia and neuropathy, even when the routine clinical investigations for mitochondrial disease are normal. Testing for this gene, unlike numerous other SCA genes, is easily undertaken as it is only 680 bp and contains no introns.

As in a previous report,8 the proportion of affected family members in affected generations was very high in the two families described here (all patients in a single generation in each of our families). This is intriguing, given that the percentage level of mtDNA heteroplasmy generally shows dramatic differences between siblings due to the germ-line mtDNA bottleneck. The sample size is small (and selection bias may be a factor), although in family A, four separate individuals have heteroplasmy ranging from 95% to 99%. This highly restricted range of heteroplasmy suggests the possibility that the inheritance of mtDNA heteroplasmy in these families is different from other mtDNA mutations (for further discussion refer to the online supplementary file). For the mutations described here, the clinical recurrence risk appears to be extremely high, and the proportion of affected family members is much higher than that expected for an autosomal dominant disorder. This provides a further clinical clue that the underlying molecular diagnosis is likely to involve the mitochondrial genome.

The identification of MTATP6 mutations has management implications: to provide guidance for genetic counselling; preimplantation/prenatal genetic diagnosis9; and potential disease prevention by nuclear transfer.10 There is also preliminary evidence demonstrating improved survival of cells having the 8993T>G mutation when treated with α-ketoglutarate and aspartate, although further work will need to demonstrate benefit in vivo, and in other MTATP6 mutations.11

It is important to note that various mitochondrial disorders may include ataxia as a component of the clinical presentation, as either a background or principal feature. A detailed discussion of the various aetiologies is beyond the scope of this work although this topic was previously reviewed in detail.12

We conclude that sequencing of MTATP6 should be considered in the diagnostic work-up of undiagnosed adult-onset spinocerebellar ataxia syndromes. Our finding that three pedigrees have mutations in this gene, from a pool of only 64 pedigrees, suggests that this finding is not isolated, and may be a relatively common aetiology for these syndromes. However, we cannot exclude the possibility that referral bias may in part explain the frequency that we have discovered. Testing of this gene is rapid and inexpensive, and as we have demonstrated, this disorder cannot be excluded by normal or non-specific muscle biopsy investigations, and can be performed on leucocyte DNA.


Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:


  • See Editorial commentary, p 857

  • Funding Funding for this work originated from the Wellcome Trust, Research Council (UK), the UK NIHR Biomedical Research Centre for Ageing and Age-related disease award to the Newcastle-upon-Tyne Foundation Hospitals NHS Trust and the UK NHS Specialised Services which supports the Rare Mitochondrial Disorders of Adults and Children Diagnostic Service ( in Newcastle-upon-Tyne. GP receives funding from the Clinician Investigator Program from the University of British Columbia (Vancouver, Canada), and a Bisby Fellowship from the Canadian Institutes of Health Research. PFC is a Wellcome Trust Senior Clinical Fellow and NIHR Senior Investigator.

  • Competing interests None.

  • Patient consent Patients provided written informed consent for participation in this research. Our data are presented anonymously without any identifiers and, therefore, we did not obtain additional consent for submission of this work to Journal of Neurology, Neurosurgery and Psychiatry.

  • Ethics approval Ethics approval was granted by the Newcastle University Clinical Research Ethics Board.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles